open access

Vol 88, No 2 (2017)
Review paper
Published online: 2017-02-28
Get Citation

Transdermal hormone replacement therapy with nanostructured medicines

Fatemeh Abdi, Tayebeh Darooneh, Maryam Ghorbani, Farzaneh Banihashemi, Nasibeh Roozbeh
DOI: 10.5603/GP.a2017.0018
·
Pubmed: 28326520
·
Ginekol Pol 2017;88(2):103-108.

open access

Vol 88, No 2 (2017)
REVIEW PAPERS Gynecology
Published online: 2017-02-28

Abstract

Objectives: Due to hormonal changes during the menopause, women experience a variety of perimenopause and postmenopause symptoms. This review examines the various aspects of nanostructured hormone therapy and its application in the treatments of menopausal symptoms.

Material and methods: Excerpta Medica DataBase, Medical Literature Analysis and Retrieval System Online, Web of Science, and Google Scholar were searched basing on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Seven eligible studies out of 51 related papers, which satisfied the initial search criteria, were extracted and carefully reviewed to clarify the role of nanomedicine in maintaining postmenopausal women’s health.

Results: Review of the seven eligible studies confirmed nanostructured hormone therapy as a safe and effective method for the alleviation of menopausal symptoms. According to the existing studies, nanostructured hormone therapy decreased the mean daily frequency and severity of menopausal symptoms.

Conclusion: The use of transdermal nanoformulations in hormone therapy can relieve climacteric symptoms and prevent other postmenopausal symptoms.

Abstract

Objectives: Due to hormonal changes during the menopause, women experience a variety of perimenopause and postmenopause symptoms. This review examines the various aspects of nanostructured hormone therapy and its application in the treatments of menopausal symptoms.

Material and methods: Excerpta Medica DataBase, Medical Literature Analysis and Retrieval System Online, Web of Science, and Google Scholar were searched basing on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Seven eligible studies out of 51 related papers, which satisfied the initial search criteria, were extracted and carefully reviewed to clarify the role of nanomedicine in maintaining postmenopausal women’s health.

Results: Review of the seven eligible studies confirmed nanostructured hormone therapy as a safe and effective method for the alleviation of menopausal symptoms. According to the existing studies, nanostructured hormone therapy decreased the mean daily frequency and severity of menopausal symptoms.

Conclusion: The use of transdermal nanoformulations in hormone therapy can relieve climacteric symptoms and prevent other postmenopausal symptoms.

Get Citation

Keywords

menopause, hormone therapy, nanostructured medicine

About this article
Title

Transdermal hormone replacement therapy with nanostructured medicines

Journal

Ginekologia Polska

Issue

Vol 88, No 2 (2017)

Article type

Review paper

Pages

103-108

Published online

2017-02-28

DOI

10.5603/GP.a2017.0018

Pubmed

28326520

Bibliographic record

Ginekol Pol 2017;88(2):103-108.

Keywords

menopause
hormone therapy
nanostructured medicine

Authors

Fatemeh Abdi
Tayebeh Darooneh
Maryam Ghorbani
Farzaneh Banihashemi
Nasibeh Roozbeh

References (36)
  1. Abdi F, Mobedi H, Mosaffa N, et al. Hormone Therapy for Relieving Postmenopausal Vasomotor Symptoms: A Systematic Review. Arch Iran Med. 2016; 19(2): 141–146.
  2. Abdi F, Kazemi F, Ramezani Tehrani F, et al. Protocol for systematic review and meta-analysis: hop (Humulus lupulus L.) for menopausal vasomotor symptoms. BMJ Open. 2016; 6(4): e010734.
  3. Heydari L, Sohrabi Z, Sayehmiri F, et al. Effect of Herbaceous Medicines effective in hot flashes of Menopause women: a systematic Review and Meta-Analysis in Iran. The Iranian Journal of Obstetrics, Gynecology And Infertility. 2014; 17: 16–25.
  4. Yazdkhasti M, Simbar M, Abdi F. Empowerment and coping strategies in menopause women: a review. Iran Red Crescent Med J. 2015; 17(3): e18944.
  5. Al-Safi ZA, Santoro N. Menopausal hormone therapy and menopausal symptoms. Fertil Steril. 2014; 101(4): 905–915.
  6. Rotem M, Kushnir T, Levine R, et al. A psycho-educational program for improving women's attitudes and coping with menopause symptoms. J Obstet Gynecol Neonatal Nurs. 2005; 34(2): 233–240.
  7. Crowe B. The Effects of Yoga Participation on Symptoms Associated with Menopause: A Mixed Methods Study. ; 2013.
  8. National Collaborating Centre for Ws, Children's H. National Institute for Health and Care Excellence: Clinical Guidelines. Menopause: Full Guideline. London: National Institute for Health and Care Excellence (UK)
  9. Copyright. Success Strategies From Women in STEM. 2015.
  10. Reid R, Blake J, Abramson B, [et al]. Menopause and osteoporosis update 2009. J Obstet Gynaecol Can. 2009;31(1 Suppl 1):S27-30.
  11. Cedars MI. Introduction: menopausal hormone therapy: where are we today? Fertil Steril. 2014; 101(4): 885–886.
  12. Gonzaga LW, Botelho MA, Queiroz DB, [et al].Nanotechnology in hormone replacement therapy: safe and efficacy of transdermal estriol and estradiol nanoparticles after 5 years follow-up study. Lat Am J Pharm. 2012;31(3):442-50.
  13. Moghimi SM, Hunter AC, Murray JC. Nanomedicine: current status and future prospects. FASEB J. 2005; 19(3): 311–330.
  14. Lehner R, Wang X, Marsch S, et al. Intelligent nanomaterials for medicine: carrier platforms and targeting strategies in the context of clinical application. Nanomedicine. 2013; 9(6): 742–757.
  15. Boisseau P, Loubaton B. Nanomedicine, nanotechnology in medicine. Comptes Rendus Physique. 2011; 12(7): 620–636.
  16. Esfandiari N. Production of Herceptin–Nanoparticles by chemical conjugation of Herceptin to Potato virus X. Iranian Journal of Breast Disease. 2013;6(3):17-27.
  17. Bathe RS, Kapoor R. Transdermal Drug Delivery System: formulation, development and evaluation-An overview. International Journal of Biomedical and Advance Research. 2015;6(1):1-10.
  18. Desai P, Patlolla RR, Singh M. Interaction of nanoparticles and cell-penetrating peptides with skin for transdermal drug delivery. Molecular membrane biology. 2010.
  19. Alexander A, Dwivedi S, Giri TK, et al. Approaches for breaking the barriers of drug permeation through transdermal drug delivery. J Control Release. 2012; 164(1): 26–40.
  20. Rees M, Moghimi SM. Nanotechnology: from fundamental concepts to clinical applications for healthy aging. Nanomedicine : nanotechnology, biology, and medicine. 2012;8 Suppl 1:S1-4.
  21. Gabellieri C, Frima H. Nanomedicine in the European Commission policy for nanotechnology. Nanomedicine. 2011; 7(5): 519–520.
  22. Botelho MA, Queiroz DB, Barros G, et al. Nanostructured transdermal hormone replacement therapy for relieving menopausal symptoms: a confocal Raman spectroscopy study. Clinics (Sao Paulo). 2014; 69(2): 75–82.
  23. Simon JA. ESTRASORB Study Group. Estradiol in micellar nanoparticles: the efficacy and safety of a novel transdermal drug-delivery technology in the management of moderate to severe vasomotor symptoms. Menopause. 2006; 13(2): 222–231.
  24. Boxenbaum H, Muenz L. Pharmacokinetics of Estrasorb®, a topical lotion for treatment of postmenopausal vasomotor symptoms. J Soc Gynecol Invest. 2002; 9: 238A.
  25. Simon JA. Estradiol topical emulsion for the treatment of moderate-to-severe vasomotor symptoms associated with menopause. 2007.
  26. Taylor MB, Gutierrez MJ. Absorption, bioavailability, and partner transfer of estradiol from a topical emulsion. Pharmacotherapy. 2008; 28(6): 712–718.
  27. Botelho M, Queiroz D, Carvalho C, et al. Effects of a transdermal testosterone metered-dose nanoemulsion in peri- and postmenopausal women: a novel protocol for treating low libido. Medical Express. 2015; 2(5).
  28. Escobar-Chávez JJ. Current Technologies to Increase the Transdermal Delivery of Drugs: Bentham Science Publishers; 2010.
  29. Rees M, Moghimi SM, Rees M, et al. Nanotechnology: from fundamental concepts to clinical applications for healthy aging. Maturitas. 2012; 73(1): 1–4.
  30. de Vargas BA, Bidone J, Oliveira LK, et al. Development of topical hydrogels containing genistein-loaded nanoemulsions. J Biomed Nanotechnol. 2012; 8(2): 330–336.
  31. Valenzuela P, Simon JA, Valenzuela P, et al. Nanoparticle delivery for transdermal HRT. Maturitas. 2012; 73(1): 74–80.
  32. Chien T-Y. Transdermal hormone delivery system: compositions and methods. Google Patents; 2012.
  33. Kheradmandnia S, Vasheghani-Farahani E, Nosrati M, et al. Preparation and characterization of ketoprofen-loaded solid lipid nanoparticles made from beeswax and carnauba wax. Nanomedicine. 2010; 6(6): 753–759.
  34. Canonico M, Fournier A, Carcaillon L, et al. Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study. Arterioscler Thromb Vasc Biol. 2010; 30(2): 340–345.
  35. Olié V, Plu-Bureau G, Conard J, [et al]. Canonico M, Scarabin P-Y. Hormone therapy and recurrence of venous thromboembolism among postmenopausal women. Menopause. 2011;18(5):488-93.
  36. Renoux C, Dell'aniello S, Garbe E, et al. Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study. BMJ. 2010; 340: c2519.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl